Read updates from clinical trials and scientific research on Huntington’s disease from Day 1 of the 2022 HDF Milton Wexler Biennial Symposium #HDF2022
uniQure is conducting safety trials of the first gene therapy for HD. A recent press release provided a 1 year update on the first group of 10 people who underwent surgery to receive this experimental drug. Let’s talk more about what it means.
A new study by researchers at Johns Hopkins describes a non-invasive way to track progression of Huntington’s disease. This could be used before patients even start showing symptoms to help test treatments in early stages of disease.
We know that HD-related changes can occur many years before symptom onset, but how early do those changes begin? A team of researchers set out to determine that with a new comprehensive study in pre-manifest HD young adults.
HDBuzz reports from the annual Huntington’s disease therapeutics conference in Palm Springs
New tools to bridge the gap between the lab and patients in our update from day 2 of the 2019 HD Therapeutics conference
Critical Path Institute launches new initiative to get HD drugs licensed as quickly as possible
A potential HD biomarker has been uncovered in a recent clinical study
HDBuzz summarises all the science from the 2017 Huntington's Disease Therapeutics Conference in Malta - day 2